Table 3.
Characteristics of psoriasis patients with abnormal Anti TPO Ab
| Baseline characteristics | Anti-TPO Antibody | |||
|---|---|---|---|---|
| Normal n=251 (%) | Abnormal n=39 (%) | P | ||
| Gender | Males (M) | 173 (68.92) | 25 (64.10) | 0.5498 |
| Females (F) | 78 (31.08) | 14 (35.90) | ||
| M: F | 2.22:1 | 1.79:1 | ||
| Age | Range | 13-75 | 16-65 | |
| Mean | 42.2 | 39.0 | ||
| ≤40 years | 99 (39.4) | 23 (59.0) | 0.0213 | |
| ≥41 years | 152 (60.6) | 16 (41.0) | ||
| Duration of psoriasis | Range | 1mo-30 years | 6mo-30 years | |
| Mean | 5.06 years | 5.39 years | ||
| ≤5 years | 144 (57.4) | 26 (66.7) | 0.2734 | |
| >5 years | 107 (42.6) | 13 (33.3) | ||
| PASI score (severity) | ≤6 (mild) | 143 (57.0) | 26 (66.7) | 0.2539 |
| >6(moderate to severe) | 108 (43.0) | 13 (33.3) | ||
| BSA | <10% (mild) | 136 (54.2) | 29 (74.4) | 0.5503 |
| ≥10% (moderate to severe) | 115 (45.8) | 10 (25.6) | ||
BSA=Body surface area; PASI=Psoriasis area severity index; mo=Month, TPO=Thyroid peroxide. P<0.05 calculated at 5% level (95% confidence limit) was considered statistically significant